Non-coding RNAs as Putative Biomarkers of Cancer-Associated Cachexia.
HNSCC (head and neck squamous cell carcinoma)
cachexia
liquid biopsy
miRNA
myomiR
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
02
2020
accepted:
27
03
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
epublish
Résumé
Cachexia is a complex metabolic syndrome that determines a severe body weight loss characterized by a marked reduction in muscle mass. About 80% of patients with advanced cancer develop cachexia due to both the tumor itself and cancer treatment (radiotherapy and/or chemotherapy), which is associated to a worse prognosis. Despite its clinical relevance, this syndrome is still under-diagnosed and it lacks effective treatments. Radio-chemotherapy treatment is essential in patients with advanced head and neck cancers (HNSCC). Although this treatment has improved patients' life expectancy, it has also dramatically increased their need for assistance and support. The management of adverse symptoms, including cachexia, is of great importance in order to avoid delays in therapy, reduction of dosages and hospitalizations. MicroRNAs (miRNAs) are small non-coding RNA molecules, which have emerged as powerful biomarkers in stratifying human cancers. Due to their high stability in body fluids, miRNAs might be excellent non-invasive biomarkers for the early detection and follow-up of cancer patients. Here, we will summarize the current knowledge and debate the strong need to identify circulating biomarkers for the early diagnosis of cachexia. We will propose circulating non-coding RNAs as biomarkers for detecting early cachexia and implementing specific treatment. We will also discuss the potential use of circulating miRNAs as biomarkers of cachexia in HNSCC patients' blood samples collected before and after radio-chemotherapy treatment. Our intent is to pave the way to the identification of specific circulating miRNAs associated to cachexia occurrence and to the design of specific interventions aimed at improving the quality of life of cancer patients.
Identifiants
pubmed: 32373612
doi: 10.3389/fcell.2020.00257
pmc: PMC7187787
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
257Informations de copyright
Copyright © 2020 Donzelli, Farneti, Marucci, Ganci, Sacconi, Strano, Sanguineti and Blandino.
Références
Rep Pract Oncol Radiother. 2015 Jul-Aug;20(4):249-58
pubmed: 26109912
Head Neck. 2017 Apr;39(4):716-723
pubmed: 28000343
J Cachexia Sarcopenia Muscle. 2018 Dec;9(7):1209-1212
pubmed: 30697980
J Biol Chem. 1999 Jan 8;274(2):787-94
pubmed: 9873017
Oncol Rep. 2014 Apr;31(4):1961-7
pubmed: 24549225
Int J Clin Exp Pathol. 2015 Mar 01;8(3):3097-103
pubmed: 26045823
J Cachexia Sarcopenia Muscle. 2020 Apr;11(2):452-463
pubmed: 31828982
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Nutrition. 2019 Oct;66:11-15
pubmed: 31177056
Cancer Sci. 2010 Oct;101(10):2087-92
pubmed: 20624164
Cell Death Dis. 2017 Sep 7;8(9):e3045
pubmed: 28880270
Front Genet. 2019 May 16;10:478
pubmed: 31156715
PLoS One. 2015 May 08;10(5):e0125094
pubmed: 25955720
Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4525-9
pubmed: 24616506
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Physiol Genomics. 2017 May 1;49(5):253-260
pubmed: 28341621
Cancer Manag Res. 2019 Jan 22;11:969-979
pubmed: 30774425
Carcinogenesis. 2018 Feb 9;39(2):293-304
pubmed: 29236960
Am J Physiol Endocrinol Metab. 2014 Feb;306(3):E267-74
pubmed: 24326420
EJIFCC. 2019 Jun 24;30(2):114-127
pubmed: 31263388
Eur J Cancer. 2013 Nov;49(16):3442-9
pubmed: 23810247
Nat Rev Mol Cell Biol. 2019 Jan;20(1):5-20
pubmed: 30228348
Nat Commun. 2014 Sep 05;2:4802
pubmed: 25190313
Front Genet. 2019 Jul 18;10:626
pubmed: 31379918
J Transl Med. 2014 Jun 01;12:155
pubmed: 24885472
J Cachexia Sarcopenia Muscle. 2020 Apr;11(2):578-593
pubmed: 31849191
Front Genet. 2013 Sep 05;4:173
pubmed: 24046777
Methods Mol Biol. 2014;1107:33-50
pubmed: 24272430
Oncol Rep. 2018 Apr;39(4):1555-1564
pubmed: 29484416
Cancers (Basel). 2015 Dec 18;7(4):2466-85
pubmed: 26694467
Cell Res. 2008 Mar;18(3):350-9
pubmed: 18270520
Oncotarget. 2015 Nov 3;6(34):35183-201
pubmed: 26440147
Nat Rev Clin Oncol. 2011 Jun 07;8(8):467-77
pubmed: 21647195
Dev Biol. 2016 Feb 1;410(1):1-13
pubmed: 26708096
Free Radic Biol Med. 2013 Sep;64:95-105
pubmed: 23872025
Cell Discov. 2017 Jul 04;3:17022
pubmed: 28698800
RNA. 2008 Nov;14(11):2348-60
pubmed: 18812439
J Cell Mol Med. 2014 Oct;18(10):1913-26
pubmed: 25124875
J Biol Chem. 2014 Aug 8;289(32):21909-25
pubmed: 24891504
Cancers (Basel). 2018 Aug 30;10(9):
pubmed: 30200243
Mol Oncol. 2019 Apr;13(4):669-680
pubmed: 30719845
Int J Biochem Cell Biol. 2013 Oct;45(10):2186-90
pubmed: 23831839
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2110-6
pubmed: 22753494
J Cachexia Sarcopenia Muscle. 2017 Jun;8(3):405-416
pubmed: 28058815
Int J Mol Sci. 2018 Feb 03;19(2):
pubmed: 29401683
PLoS One. 2011;6(9):e24650
pubmed: 21949739
Mol Oncol. 2019 Oct;13(10):2278-2296
pubmed: 31402562
Curr Opin Genet Dev. 2013 Feb;23(1):3-11
pubmed: 23465882
Nat Rev Mol Cell Biol. 2019 Jan;20(1):21-37
pubmed: 30108335
Nature. 2005 Jun 9;435(7043):834-8
pubmed: 15944708
Br J Cancer. 2016 Mar 15;114(6):680-7
pubmed: 26954714
Hematology. 2017 Aug;22(7):392-397
pubmed: 28253825
Oncotarget. 2017 Feb 7;8(6):9911-9921
pubmed: 28039483
Cancer Res. 2014 Aug 15;74(16):4270-81
pubmed: 24980554
Am J Cancer Res. 2016 Jul 01;6(7):1461-93
pubmed: 27508091
Drug Dev Res. 2015 Sep;76(6):270-7
pubmed: 26082192
Int J Clin Exp Pathol. 2014 Jun 15;7(7):4194-203
pubmed: 25120799
Cancer Res. 1982;42(2 Suppl):721s-726s
pubmed: 7055813
PLoS One. 2014 Jul 14;9(7):e102413
pubmed: 25019505
Nat Rev Cancer. 2015 Jun;15(6):321-33
pubmed: 25998712
J Cachexia Sarcopenia Muscle. 2019 Jun;10(3):536-548
pubmed: 31091026
Tumour Biol. 2015 Mar;36(3):1973-81
pubmed: 25527152
FEBS Lett. 2014 Aug 19;588(16):2639-52
pubmed: 24681102
J Clin Oncol. 2010 Apr 1;28(10):1721-6
pubmed: 20194856
Biomed Rep. 2016 Oct;5(4):395-402
pubmed: 27699004
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Sci Rep. 2017 May 17;7(1):2046
pubmed: 28515477
Int J Biochem Cell Biol. 2013 Oct;45(10):2215-29
pubmed: 23770121
BMC Genomics. 2019 Jun 17;20(1):503
pubmed: 31208318